Nutritional Support for HIV-Tuberculosis Co-infected Adults in Senegal, West Africa

University of Washington26 enrolled

Overview

Food insecurity can contribute to poor adherence to both tuberculosis treatment and antiretroviral therapy (ART). Interventions that target food insecurity have the potential to improve treatment adherence and decrease mortality. The goals of this study were to determine the cost, feasibility, acceptability, and potential impact of implementing nutritional support to improve adherence and treatment completion among HIV-TB co-infected adults in the Casamance region of Senegal, West Africa.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Enrollment

Conditions

HIV and Tuberculosis Co-infection

Interventions

Food basketDIETARY_SUPPLEMENT

Ready-to-Use Therapeutic FoodDIETARY_SUPPLEMENT

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * HIV-Tuberculosis co-infection * Age ≥18 years * Initiating treatment for tuberculosis * Provide written informed consent Exclusion Criteria: • Unwilling or unable to provide written informed consent

Outcomes

Primary Outcomes

Uptake, as determined by percent of monthly nutritional support rations received, transported, stored, and utilized by subjects.

Time frame: 6 months

Acceptability, as determined by patient reported perceptions of nutritional support.

Time frame: 6 months

Costs of monthly nutritional support rations.

Time frame: 6 months

Secondary Outcomes

Tuberculosis treatment adherence as determined by Medication Possession Ratio

Time frame: 6 months

Tuberculosis treatment adherence as determined by patient reported number of missed doses in the previous 7 days and 4 weeks.

Time frame: 6 months

Tuberculosis treatment completion defined as completing full course of prescribed therapy

Time frame: 6 months

Adherence to antiretroviral therapy as determined by Medication Possession Ratio

Time frame: 6 months

Adherence to antiretroviral therapy as determined by patient reported number of missed doses in the previous 7 days and 4 weeks

Time frame: 6 months

CD4 cell count

Time frame: 6 months

Presence of acid fast bacteria using sputum smear microscopy

Time frame: 6 months

Results of GeneXpert

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.